M
Last Price
52 Week Range
€5.60 - €10.40
Next Earnings Date
Feb 17 2026 (Estimate)
Next Earnings Date
Feb 17 2026 (Est.)
Last Price
Market Cap | €35.93M |
EV | €-26.17M |
Shares Outstanding | 4.33M |
Beta | 0.46 |
Industry | Drug Manufacturers - Specialty & Generic |
Analyst Rating | BUY |
Analyst Target Price | |
Number of Analysts | 1 |
P/E 2021E | - |
P/Revenue 2021E | - |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2021E | - |
Net Profit Margin 2021E | - |
ROE 2021E | - |
ROCE 2020 | 39.58% |
DPS 2021E | - |
Payout Ratio 2021E | - |
Div. Yield 2021E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y
M
Malin Corporation plc
MLC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Data Unavailable
Employees
2
Website
www.malinplc.comIPO Date
2014-03-25
Headquarters
The Lennox Building, 50 Richmond Street South, Dublin, Co. Dublin, D02 FK02, Ireland
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.